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Abstract
Background The receptor for the cytokine TWEAK
(TweakR) is a cell surface member of the tumor necrosis
factor receptor superfamily with diverse biological roles.
TNFRSF family members are appealing therapeutic targets
in oncology due to their aberrant expression and function in
tumor cells. The goal of the current study was to examine
the potential of TweakR as a therapeutic target in breast
cancer.
Methods Expression of TweakR in primary breast cancer
tissues and metastases was characterized using immuno-
histochemistry. To determine the functional relevance of
TweakR, breast cancer cell lines were treated in vitro and
in vivo with enavatuzumab, a humanized mAb against
TweakR.
Results Overexpression of TweakR was observed in
infiltrating tumors compared to normal adjacent breast
tissues, and strong staining of TweakR was observed in all
subtypes of invasive ductal breast cancer. In addition, a
positive correlation of TweakR and HER2 expression and
co-localization were observed, irrespective of ER status.
TweakR expression was also observed in bone metastasis
samples from primary breast cancer but rarely in benign
tumors. Enavatuzumab inhibited the in vitro growth of
TweakR-expressing breast cancer cell lines, and this
activity was augmented by cross-linking the mAb. In
addition, enavatuzumab significantly inhibited the in vivo
growth of multiple breast cancer xenograft models
including a model of metastasis.
Conclusions TweakR is highly expressed in all subtypes
of invasive ductal breast cancer, and enavatuzumab
administration exhibited a dose-dependent inhibition of
primary tumor growth and lung metastasis and enhanced
the antitumor activity of several chemotherapy agents
currently used to treat breast cancer. These data provide the
rationale to evaluate enavatuzumab as a potential therapy
for the treatment of breast cancer.
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Introduction
Breast cancer is the most common cancer in women world-
wide. An estimate of more than 1.6 million new cases of
breast cancer occurred among women in 2010 (Forouzanfar
et al. 2011). Prognosis and selection of therapies are often
influenced by clinical and pathological features including
expression of specific tumor markers such as ER/PR and
HER2. In addition to standard chemotherapies, endocrine
therapies (e.g., estrogen receptor antagonists and aromatase
inhibitors) are used to treat ER-positive tumors, while
trastuzumab (anti-HER2 mAb) is a standard of care for
treating HER2-positive cases. Even though significant
progress has been made in the treatment of breast cancer,
there remains a need for new treatments, especially for
patients with more aggressive tumors and in advanced
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stages. In fact, metastasis of primary breast tumor cells to
distant organs is responsible for the majority of breast
cancer deaths (Hurvitz 2011).
TWEAK receptor (TweakR, Fn14, TNFRSF12A) is a
cell surface protein and member of the tumor necrosis
factor receptor superfamily and is activated by its ligand,
TWEAK (Wiley et al. 2001; Winkles 2008). TweakR was
first described as an FGF-inducible gene which played a
role in fibroblast adhesion and migration (Meighan-Mantha
et al. 1999). Subsequently, the induction of TweakR
expression by other growth factors and/or upon tissue
injury was observed in multiple cell types, including
hepatocytes, endothelial cells, adipocytes, and cardiomyo-
cytes. These observations and additional studies have
suggested that the TWEAK/TweakR interaction may play a
role in tissue repair and inflammation (Campbell et al.
2004; Chacon et al. 2006; Chorianopoulos et al. 2010; Feng
et al. 2000; Jakubowski et al. 2005). The initial identifi-
cation of TWEAK as a weak inducer of apoptosis, along
with a role in the regulation of migration and angiogenesis,
demonstrates the pleiotropic nature of the TWEAK/
TweakR system (Harada et al. 2002; Jakubowski et al.
2002; Lynch et al. 1999; Nakayama et al. 2002; Schneider
et al. 1999; Wiley et al. 2001).
Previously, we have reported the overexpression of
TweakR in many types of solid tumors and demonstrated
the therapeutic potential of a mAb targeting TweakR
(enavatuzumab, formerly PDL192) (Culp et al. 2010).
Here, we expand the analysis to the role of TweakR in
breast cancer. We show that TweakR is overexpressed on
different subtypes of primary patient samples and demon-
strate a correlation of TweakR and HER2 expression. We
also provide a functional rationale for the use of ena-
vatuzumab in the treatment of breast cancer with in vitro
and in vivo studies on breast cancer cell lines.
Materials and methods
Tissues and immunohistochemistry staining
Immunohistochemistry analysis for TweakR was per-
formed on primary breast cancer samples as previously
described (Culp et al. 2010). Matched normal adjacent and
cancer tissues were collected from surgery specimen of
breast cancer patients by Zoion Diagnostic (Shrewsbury,
MA) with appropriate IRB approval at participating clini-
cal sites. TweakR staining was scored based on percentage
of epithelial cells stained in the sample (0, \10 %; 1?,
11–25 %; 2?, 26–50 %; 3?, 51–75 %; 4?,[75 %). Two
hundred and thirty-seven samples were also stained for
HER2 using anti-HER2 mouse mAb (clone CB11, BioCare
Medical, Concord, CA) and for estrogen receptor (ER)
using anti-ER mouse mAb (clone 1D5, BioCare Medical).
Samples were considered HER2 positive with IHC score
C2?; ER was considered positive if the sample had[10 %
of epithelial cells stained positive. All stainings were
scored by a board-certified oncology pathologist.
Co-staining of TweakR and HER2 was performed in 40
invasive ductal breast cancer samples on a tissue micro-
array with the two-step procedure. First, the samples were
stained for TweakR expression with an internal mouse
mAb (374.2) and detected by MACH4-HRP system; sub-
sequently, the samples were stained with a rabbit mAb
(EP1045Y, Biocare Medical) for HER2 expression and
detected with MACH4-AP system.
Cell lines and reagents
All tumor cell lines were purchased from American Type
Culture Collection (Manassas, VA) except the BT549 and
MX1 cell lines, which were obtained from DTP/DCTD
Tumor Repository at the National Cancer Institute
(Frederick, MD), and the MB231 variant cell line, which was
derived from the MDA-MB-231 cell line for its increased
metastatic potential in vivo. All purchased cell lines were
maintained in the growth medium recommended by the
vendor, and the MB231 variant cell line was maintained in
IMDM supplemented with 10 % fetal bovine serum.
The anti-TweakR monoclonal antibody 374.2 was gen-
erated by immunizing Balb/c mice with a synthetic peptide
comprising amino acids 37–49 (SRGSSWSADLDKC) of
the human TweakR coding region. Hybridomas were
screened for TweakR specificity by Western blot and
immunohistochemistry (IHC) on samples with known
levels of TweakR expression. Enavatuzumab, a humanized
anti-TweakR antibody, was previously described (Culp
et al.). The human IgG1 control antibody, MSL109, is a
fully human antibody to cytomegalovirus (Drobyski et al.
1991). The cross-linking secondary antibody was pur-
chased from Jackson Immunoresearch (Cat# 109-006-008,
West Grove, PA). Trastuzumab (Herceptin) was pur-
chased from Genentech (South San Francisco, CA).
TweakR was measured on cell lines by flow cytometry
using enavatuzumab, followed by a fluorescein iso-
thiocyanate-conjugated anti-human secondary antibody
(Life Technologies, Carlsbad, CA). Expression was
reported as the fold increase in mean fluorescence intensity
versus control antibody-stained cells. Cell lines were con-
firmed to be of the HER2, luminal, or basal subtype by
measuring ErbB3, EGFR, E-cadherin, EpCAM, HER2, and
CD44 expression by flow cytometry (see Supplemental
Methods, Supplemental Table 2). Expression of additional
luminal or basal-specific genes (Finn et al. 2009; Neve
et al. 2006) was assessed in a subset of cell lines by
microarray analysis (Supplemental Table 3).
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Growth inhibition assay
Proliferation assays were performed by incubating
300–2,000 cells in 96-well plates with enavatuzumab in the
presence or the absence of a cross-linking secondary anti-
body at a 2:1 (primary: secondary) ratio. Cell density per
well was determined based on growth property for each
cell line. For samples treated with immobilized antibody,
ELISA plates (Immulon 4HBX, Thermo Scientific,
Rochester, NY) were coated with antibody at the indicated
concentrations, incubated for 24 h at 4 C, and washed
three times with PBS prior to plating cells. When untreated
cells were *80 % confluent, five to 10 days after plating,
cell viability was assayed using resazurin (25 lM, #R7017,
Sigma, St. Louis, MO) for 2 h at 37 C. Relative viability
was calculated by dividing the viability of anti-TweakR
antibody-treated samples with that of control antibody-
treated cells. In most cases, assay results represent the
readings from triplicate wells. Each assay was performed at
least twice, and representative data are shown.
For synergy analysis with trastuzumab, 500 SKBR3
cells were seeded in 96-well plates, and antibodies were
added 24 h later. Cells were incubated with enavatuzumab
(10–0.006 lg/mL) with half-molar ratio of cross-linking
antibody, trastuzumab alone (1–0.0006 lg/mL), or titra-
tions of one antibody in the presence of constant concen-
trations of the other. The presence of cross-linking
antibody had no effect on the activity of trastuzumab. Ten
days later, cell viability was assessed with resazurin
(Sigma).
Synergy analysis was performed by calculating the
combination index (CI) at multiple effect sizes using the
Chou–Talalay method (Chou 2010): CI = (Cecomb/Cealone) ?
(Ctcomb/Ctalone), where Ce = the concentration of ena-
vatuzumab and Ct = concentration of trastuzumab, to
achieve a particular effect size. CI \ 0.9 = synergy,
1.1 C CI C 0.9 = additivity, and CI [ 1.1 = antagonism.
Synergy was observed at the majority of antibody con-
centrations at effect sizes from 30 to 60 % inhibition, with
smaller CI obtained at larger effect sizes (Supplemental
Figure 1). CI could not be calculated at effect sizes greater
than 60 % inhibition, as trastuzumab monotherapy did not
result in more than 60 % inhibition.
Xenograft tumor studies
Tumor cells were inoculated into the mammary fat pad of
6-week-old severe combined immunodeficient (SCID)
mice (IcrTac:ICR-Prkdc\scid[, Taconic, Germantown, NY)
at 1 9 107 cells per mouse. For the MCF-7 model, animals
were also implanted with 17b-estradiol pellets (0.36 mg,
60 day release, Innovative Research of America, Sarasota,
FL). Animals were randomized into groups when the mean
tumor volume reached 100–120 mm3. Antibodies were
administered intraperitoneally three times per week for
3 weeks. Gemcitabine (Gemzar, Eli Lilly, IN) and vino-
relbine (Navelbine, Sicor, Irvine, CA) were dosed intra-
peritoneally twice a week for three weeks. Tumor volumes
(LxWxH/2) were measured on dosing days; the group
means ? SEM are displayed. Groups were removed from
the study when at least one tumor in the group reached the
allowable limit (1,500 mm3). The statistical significance of
the differences between groups was determined by T test
using SAS statistical software. Mean tumor volumes
between groups were considered significantly different if
p B 0.05. All animal work was carried out under NIH
guidelines ‘‘Guide for the Care and Use of Laboratory
Animals’’ using IACUC approved protocols.
Lung metastases were quantified in the MB231 variant
study on day 37. Mouse lungs (5 animals per dose group)
were fixed in formalin and stained for human cytokeratin
7/8 (Cam5.2 antibody) at Mosaic Laboratories (Lake
Forest, CA). The tissues were scanned using ScanScope
software (Aperio, Vista, CA), and cytokeratin-positive
cells were quantified using ImageScope software (Aperio).
Both the numbers of micrometastases (individual cells and
clusters of less than 4 cells) as well as the numbers of
metastases with more than 4 cells per cluster were
quantified.
Results
TweakR expression is elevated in invasive
ductal breast tissues
TweakR expression was evaluated in 522 paraffin samples
of primary breast tissues and metastases by immunohisto-
chemistry (IHC). Over thirty percent (119/378) of invasive
ductal breast cancer had strong staining of TweakR, but
only 1 out of 46 cases of lobular breast cancers was posi-
tive (Supplemental Table S1). TweakR expression was
evaluated on eleven matched pairs of breast cancer and
normal adjacent tissue. TweakR was detected in nine of
eleven cases, and in each case, TweakR expression was
elevated in the infiltrating tumor compared to normal tissue
(Fig. 1a, b). In some tumor samples, TweakR staining was
observed on stroma cells and the vasculature in addition to
the tumor epithelial cells (data not shown).
Development of breast cancer progresses through stages
of hyperplasia, benign lesions, and DCIS before the tumors
become invasive. Lymph nodes and bones are two common
organs for breast cancer metastasis. No TweakR staining
was observed on a panel of hyperplasia or benign breast
tissues, and only one of 18 DCIS cases was positive. In
contrast, TweakR expression was detected in 5 out of 10
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bone metastases (Fig. 1c) and 3 out of 30 lymph node
samples from patients with metastatic breast cancer
(Supplemental Table 1). These findings are consistent with
a previous report of high TweakR expression correlating
with metastatic breast cancer (Willis et al. 2008).
TweakR expression correlates with HER2 expression
Breast cancers are often categorized into different subtypes
according to their HER2 and ER status. A subset of the
invasive breast cancer samples (237 cases) that had been
stained for TweakR expression was also stained for HER2
and ER to determine whether their expression correlated
with TweakR expression. TweakR expression was con-
sidered positive if the staining was observed on more than
25 % of epithelial cells (IHC score C 2?). Using the chi-
square test of independence, TweakR and HER2 expres-
sion were found to be significantly associated, with a
p value of 1.129E-10 (Table 1). Approximately 60 % of
HER2-positive cases also expressed TweakR, while fewer
than 25 % of HER2-negative cases stained positive for
TweakR. On the contrary, no such correlation was
observed between TweakR and ER expression. These
observations are consistent with previously published data
(Willis et al., 2008). Co-immunostaining of TweakR and
HER2 was performed on a subset of TweakR?/HER2?
breast cancer samples to determine whether TweakR and
HER2 were expressed in the same cells within a tumor. In
these samples, membranous HER2 staining clearly coin-
cided with cytoplasmic and membranous TweakR staining
in the majority of tumor cells (Fig. 1d).
In vitro growth inhibition by enavatuzumab is enhanced
upon cross-linking in all subtypes of breast cancer cell
lines
Enavatuzumab is a humanized anti-TweakR antibody that
exhibits potent antitumor activity in vitro and in vivo on
cell lines derived from a variety of tumor types (Culp et al.
2010). To characterize further the functional activity of
enavatuzumab in breast cancer, a panel of TweakR-
expressing breast cancer cell lines was evaluated for sen-
sitivity to enavatuzumab in proliferation assays in vitro.
This panel included cancer cell lines reflecting all subtypes
A B
C D
Fig. 1 TweakR is expressed in invasive breast cancer samples and is
co-expressed with HER2. Immunohistochemistry staining for
TweakR expression was performed in normal adjacent tissue
(a) and infiltrating tumor tissue (b) from the same case of breast
cancer (2009 magnification). c TweakR expression in bone metas-
tases from breast cancer (2009 magnification). d Double staining of
TweakR (brown) and HER2 (Red) in a ductal breast cancer sample
(4009 magnification). Representative images are shown here
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of breast cancer, as previously defined by their molecular
profile (Finn et al. 2009; Hu et al. 2009; Hurvitz and Finn
2009; Neve et al. 2006). Expression of HER2 and luminal-
or basal-specific markers was confirmed on the panel by
flow cytometry and/or microarray analysis (Supplemental
Table S2 and S3). In general, subtype classification of the
cell lines was in agreement with that reported by others.
The breast cancer cell lines were treated with ena-
vatuzumab in a soluble form, cross-linked in solution with
a secondary antibody, or immobilized enavatuzumab.
Soluble enavatuzumab significantly and reproducibly
inhibited the growth of 5 of 27 cell lines by[20 %, while
cross-linked or immobilized enavatuzumab had more
potent effects in a larger subset of cell lines, 13 of 27 lines
and 18 of 27 cell lines exhibited[20 % growth inhibition,
respectively (Table 2; Fig. 2a). Cross-linking increased
both the number of cell lines sensitive to enavatuzumab
and the potency of the antibody, as evidenced by the
relative decrease in EC50 values of cross-linked versus
soluble antibody treatment. In contrast, while immobili-
zation significantly increased the maximal inhibition by
enavatuzumab over cross-linked antibody, the EC50
increased for most cell lines when the antibody was
immobilized versus cross-linked antibody (Table 2). The
higher EC50 likely reflects a dependence on physical
proximity between adjacent immobilized antibody mole-
cules to enable cross-linking of cell surface TweakR
molecules. Sensitivity to enavatuzumab was observed in all
subtypes of breast cancer expressing antigen yet did not
appear to correlate with TweakR expression levels, as
measured by flow cytometry (Table 2).
Enavatuzumab synergizes with trastuzumab in vitro
Given the observation that enavatuzumab inhibited the
growth of breast cancer cell lines in vitro and that TweakR
expression correlated with HER2 overexpression in pri-
mary breast cancers, enavatuzumab was assessed for its
potential to synergize with trastuzumab, the standard of
care for HER2-positive breast cancer. SKBR3 cells
(HER2?) were exposed to titrations of enavatuzumab
alone, trastuzumab alone, or both drugs simultaneously in
ratios sufficient to assess cooperative interaction (Chou
2010). Synergy in tumor cell growth inhibition was
observed with the combination of enavatuzumab and
trastuzumab, as the Combination Index was found to be
less than 1.0 at multiple effect sizes (Fig. 2b, Supplemental
Figure S1).
Enavatuzumab does not stimulate invasion
or migration in vitro
TweakR has been shown to play a role in tumor cell
migration and invasion in vitro, as expression of TweakR
appears to correlate with the invasive potential of breast
cancer cell lines (Willis et al. 2008). In addition, TWEAK,
the natural ligand of TweakR, has been shown to stimulate
the adhesion, migration, and invasion of cancer cell lines
(Dai et al. 2009; Tran et al. 2003). Enavatuzumab can
activate signaling pathways downstream of TweakR, but
has moderate agonist activity compared to TWEAK (Culp
et al. 2010). Given the ability of TWEAK to stimulate
migration and invasion of tumor cells, enavatuzumab was
assessed for its ability to stimulate migration or invasion of
breast cell lines in vitro. Cell lines with detectable but basal
levels of invasiveness were assessed in an invasion assay,
while cell lines with low innate invasive potential were
assessed in a migration assay. TWEAK stimulated
migration/invasion of 4 of 7 cell lines tested, while
enavatuzumab did not stimulate invasion of any cell lines
and enhanced the migration of just one cell line tested,
MB453 (Supplemental Table S4, Supplemental Figure S2).
Of the seven evaluated, soluble enavatuzumab had inhib-
ited the proliferation of three cell lines. For one such line,
SKBR3, TWEAK also enhanced invasion. Notably, ena-
vatuzumab did not significantly stimulate invasion by this
cell line (Supplemental Figure S2).
Therapeutic effect of enavatuzumab in xenograft
models of breast cancer
In a previous study, enavatuzumab was found to exhibit
potent antitumor activity in mouse xenograft models
derived from several tumor types. However, as no breast
cancer models were tested in those studies, enavatuzumab
was next evaluated for its potential therapeutic effect in
breast cancer models in vivo. Enavatuzumab exhibited
potent antitumor activity in multiple xenograft models,
including MCF-7, an ER-positive breast cancer cell line
(Fig. 3a), and HCC70, a triple-negative (ER-/PR-/
HER2-) line (Fig. 3b). In the MCF-7 model, ena-
vatuzumab induced tumor regression in all animals,
with complete eradication observed for 5/10 tumors.
Table 1 Positive correlation of TweakR expression with HER2
overexpression
Type N TWEAKR IHC score C2 (%)
positive
0 1 2 3 4
ER ?/HER2? 63 14 12 11 16 10 37/63 59
ER ?/HER2- 51 34 5 5 4 3 12/51 24
ER-/HER2? 57 9 10 7 17 14 38/57 67
ER-/HER2- 66 37 16 6 3 4 13/66 20
Total 237 94 43 29 40 31 100/237 42
Using the chi-square test, TweakR and HER2 expression were found
to be significantly associated (p value = 1.129E-10)
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In the HCC70 model, enavatuzumab largely stabilized
tumor growth. In a third model, the triple-negative MB231
variant model, enavatuzumab was assessed for its effect on
both primary tumor growth and on the development of
metastases. In this model, enavatuzumab treatment sup-
pressed primary tumor growth in the mammary fat pad,
with a clear dose–response relationship (Fig. 3c). In addi-
tion, enavatuzumab significantly inhibited the development
of lung metastases in this model (Fig. 3d, e). The growth of
micromets (\4 cells) and macromets (C4 cells) were
similarly inhibited by enavatuzumab.
In the MB231 variant model, enavatuzumab was also
tested in combination with gemcitabine and vinorelbine,
agents that are commonly used to treat patients with
triple-negative breast cancer. A suboptimal dose of
enavatuzumab (1 mg/kg) was used in this study and alone
had no significant impact on tumor growth (Fig. 4).
However, enavatuzumab at this dose level enhanced the
antitumor effects of both gemcitabine and vinorelbine, with
complete eradication observed in 3 of 10 mice in the
enavatuzumab/gemcitabine combination and in 7 of 7
tumors with the enavatuzumab/vinorelbine combination
(Fig. 4).
Discussion
Our study of the TweakR IHC analysis covered a wide
range of breast tissue samples showing minimal TweakR
expression in normal, hyperplasia, benign, DCIS, and
Table 2 Enavatuzumab inhibits breast cancer cell growth in vitro
Subtype TweakR expression Inhibition of proliferation by enavatuzumab
Soluble ?xlinker Immobilized
10 lg/mL EC50 (lg/mL) 10 lg/mL EC50 (lg/mL) 10 lg/mL EC50 (lg/mL)
BT20 B 7.5 – - - - ? 1.21
BT474 H 2.3 - - - - ± 1.85
BT483 L 2.5 - - ? 2.30 ??? 1.48
BT549 B 4.7 ? 1.32 ?? 0.20 ?? 0.72
Cama1 L 3.8 - - ? 1.57 ?? 2.16
DU4475 B 1.5 - - - - - -
HCC1143 B 3.4 - - ? 0.18 ? 1.31
HCC1428 L 1.4 - - ± 1.85 ? 1.77
HCC1500 B 2.7 - - ± 1.75 ??? 1.60
HCC1569 H 2.8 - - ± 0.32 - -
HCC1937 B 5.3 ± 4.46 ? 0.42 ? 2.38
HCC38 B 6.6 ? 0.31 ?? 0.31 ?? 1.53
HCC70 B 2.4 - - ? 0.23 ± 2.30
Hs578T B 4.8 - - - - - -
MB231 variant B 8.3 ? 2.98 ? 0.15 ?? 1.33
MCF7 L 5.8 - - ± 0.41 ? 1.27
MDA-MB157 B 5.9 - - ± 0.06 ? 1.20
MDA-MB175 VII L 1.4 - - - - - -
MDA-MB231 B 10.3 ? 1.99 ? 0.35 ? 1.02
MDA-MB361 H 4.7 - - - - - -
MDA-MB453 H 2.6 - - ? 1.04 ? 2.59
MDA-MB468 B 8.8 ? 0.31 ? 0.52 ??? 1.10
MX1 B 4.7 - - ? 0.71 ?? 1.08
SKBR3 H 2.3 ± 1.93 ? 0.50 ?? 1.36
T47D L 1.8 - - - - - -
ZR-75-1 L 1.9 - - - - ? 1.48
ZR-75-30 H 1.6 - - - - - -
B basal, L luminal, H HER2?
TweakR expression: fold increase of TweakR versus control
Inhibition score: - \10 %, ±10–20 %, ?20–50 %, ??50–75 %, ??? [75 %, nt not tested
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invasive lobular breast cancer tissues while demonstrating
increased TweakR expression in invasive ductal breast
cancer, LN, and bone metastases from breast cancer
patients. TweakR expression was found to be overexpres-
sed on all subtypes of invasive ductal breast cancer, and
TweakR positively correlated with HER2 overexpression,
consistent with a previous report (Willis et al. 2008). Our
novel finding that these proteins are co-expressed in breast
tumor epithelial cells and the observation that ena-
vatuzumab and trastuzumab synergize in inhibiting the
growth of HER2-positive breast cancer cells in vitro sug-
gests a functional interaction between these two proteins.
Synergy in vitro was observed in multiple cell lines, but
only in trastuzumab sensitive, HER2 overexpressing lines
(SKBR3, ZR-75-30, and MDA-MB-453); however, syn-
ergy was unable to be confirmed in vivo, as none of these
cell lines formed tumors reproducibly to enable xenograft
studies. HER2 overexpressing cell lines appeared to be
innately less sensitive to enavatuzumab than other sub-
types, as 2 of 6 HER2 overexpressing lines were sensitive
to soluble, cross-linked, or immobilized antibody. How-
ever, the finding of synergy with trastuzumab suggests that
this subset of patients may benefit from the addition of
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Fig. 2 Growth inhibition of breast cancer cell lines by enavatuzumab
and synergy of inhibition when combined with trastuzumab.
a–d BT549 (a), HCC38 (b), MB231 variant (c), and HCC70
(d) breast cancer cells were incubated with soluble enavatuzumab
or human IgG1 control antibody in the presence (x, D) or absence
(filled triangle, not shown) of cross-linking antibody, or immobilized
enavatuzumab or control antibody (filled square, not shown) for
5–10 days. Relative viability was calculated by dividing the viability
of treated cells by that of untreated cells. Representative data are
shown here (point, mean of triplicate wells; bars, SEM). All
experiments were repeated at least twice (E?F). SKBR3 cells were
incubated with titrations of trastuzumab (e) or enavatuzumab with
cross-linking secondary antibody (f) in the presence or absence of a
single concentration of the other antibody (0.16 lg/mL trastuzumab
and 0.26 lg/mL enavatuzumab are shown). At the effect size of 60 %
inhibition (dashed line), the combination index (CI) was 0.27 for
the enavatuzumab ? trastuzumab combination and 0.28 for the
trastuzumab ? enavatuzumab combination, suggesting significant
synergy between the two antibodies. Synergy was observed at the
majority of antibody concentrations tested at effect sizes from 30 to
60 % inhibition (Supplemental Figure S1)
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Some of the cell lines with the greatest sensitivity to
enavatuzumab included those of the basal subtype, also
categorized as triple-negative tumors, as they lack
expression of estrogen receptor, progesterone receptor, and
HER2. The standard therapy for patients with basal-type
tumors is cytotoxic chemotherapy, as no targeted therapies
currently exist for this subtype, and this patient population
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Fig. 3 Enavatuzumab inhibited the growth of primary tumors and
metastases in xenograft models of breast cancer. Established MCF7
(a) and HCC70 (b) tumors were treated with enavatuzumab or a
human IgG1 control antibody at 10 mg/kg three times per week, with
10 animals in each dosing group. Tumor volumes were measured on
each dosing day; points, mean; bars, SEM. Differences in tumor
volumes between the enavatuzumab and control treated groups were
significant (p \ 0.001) in both models. c–e Established MB231
variant tumors were treated with enavatuzumab or a human IgG1
control antibody thrice per week, with 7 mice in each dosing group.
c Tumor volumes were measured on each dosing day; points, mean;
bars, SEM. d Metastases were quantified in lungs harvested on day
37; both micrometastases (\4 cells) and metastatic clusters [4 cells
were enumerated. Enavatuzumab treatment significantly inhibited the
growth of primary tumors and micrometastases at 10, 3, and 1 mg/kg
and inhibited the development of larger metastases at 10 and 3 mg/kg
(*p \ 0.05; **p \ 0.001). e Immunohistochemical staining of human
cytokeratin-positive metastases in mouse lungs
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Basal-type tumors can be further subdivided into those that
retain the epithelial phenotype (as defined by expression of
GATA3, TOB1, and cytokeratins) and those that have
undergone epithelial-to-mesenchymal transition and
express genes typical of the mesenchymal phenotype,
including vimentin, CD44, and Axl (Neve et al. 2006).
These tumors tend to be highly invasive and appear to have
stem cell-like qualities. The finding that several cell lines
with a mesenchymal phenotype (BT549, MDA-MB231,
and MB231 variant, Supplemental Table 3) are highly
sensitive to enavatuzumab in vitro suggests that this anti-
body may provide a promising therapeutic for this popu-
lation of patients for whom current therapies offer limited
benefit.
The basal-type MB231 variant cells were also quite
sensitive to enavatuzumab treatment in vivo. These
tumors are highly invasive and metastasize readily to the
lung. In this model, enavatuzumab not only inhibited
primary tumor growth, but also significantly inhibited the
growth of tumors at metastatic sites. In this model,
metastases are generally not detectable until the primary
tumor is *500 mm3 (data not shown), and the antibody
treatments that resulted in the most dramatic decrease in
the growth of metastases (3 and 10 mg/kg) also prevented
the primary tumors from reaching 500 mm3. Thus, ena-
vatuzumab treatment may inhibit the growth of lung
metastases through several possible mechanisms including
inhibition of extravasation, induction of cell death during
migration, or inhibition of tumor seeding and/or growth in
the lung.
Importantly, metastatic growth was not enhanced by
enavatuzumab. TweakR overexpression has been shown to
enhance the invasive properties of breast cancer cells
in vitro, and stimulating TweakR signaling with TWEAK
promotes tumor cell migration (Dai et al. 2009; Tran et al.
2003; Willis et al. 2008). The inability of enavatuzumab to
stimulate invasion in vitro or metastasis in vivo may be due
to its reduced agonist activity, compared to TWEAK, and/
or may reflect the inability of in vitro assays to replicate
fully complex in vivo processes.
Previous studies have shown that enavatuzumab is a
partial agonist, directly inhibiting the growth of tumor cells
in vitro (Culp et al. 2010). This inhibitory activity has been
shown to be not through induction of apoptosis, the
mechanism first ascribed to TWEAK, but via cell cycle
arrest through activation of the NFkB pathway and
upregulation of p21 (Purcell et al. 2012) In the current
studies, growth inhibition by enavatuzumab in vitro was
enhanced in most cell lines when the antibody was cross-
linked, either in solution or by immobilization. Such
enhancement of activity by antibody cross-linking has
previously been shown for TweakR and other members of
the TNF receptor superfamily (Alzona et al. 1994; Law
et al. 2005; Mori et al. 2004; Nakayama et al. 2003).
Antibody cross-linking likely enhances the formation of
receptor multimers, which are thought to drive downstream
signaling for this family of receptors (Motoki et al. 2005).
Cross-linking of antibodies in vitro is likely to be physio-
logically relevant, as Fc receptors on immune and other
cells provide endogenous cross-linking capability for
















































Fig. 4 Enavatuzumab enhanced the antitumor activity of gemcita-
bine and navelbine in a triple-negative model of breast cancer.
Established MB231 variant xenograft tumors were treated with
enavatuzumab at 1 mg/kg thrice weekly, alone or in combination with
gemcitabine at 30 mg/kg (a) or vinorelbine at 5 mg/kg (b) twice
weekly, with 7 mice in each dosing group. Tumor volumes were
measured on gemcitabine and vinorelbine dosing days; points, mean;
bars, SEM. Differences in tumor volumes were significant (p \ 0.05)
between the gemcitabine and enavatuzumab/gemcitabine treatment
groups and the vinorelbine and enavatuzumab/vinorelbine treatment
groups on days 22–34. The data shown in a and b were derived from a
single study. A second study yielded similar results
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antibodies in vivo (Wilson et al. 2011). Indeed, ena-
vatuzumab treatment in multiple xenograft models has
been found to enhance tumor infiltration of immune cells,
which would enable Fc–Fc receptor (Fc–FcR) interactions
(Ye et al. 2012). For several antibodies, Fc–FcR interac-
tions have been shown to have therapeutic consequences,
as patients bearing high-affinity alleles of FccRIIIA exhibit
increased responses to trastuzumab and rituximab com-
pared to patients with low-affinity alleles (Cartron et al.
2002; Varchetta et al. 2007; Weng and Levy 2003).
While one functional consequence of enhanced Fc–FcR
interactions may be increased antibody-dependent cellular
cytotoxicity (ADCC), for some cell surface proteins,
receptor clustering and enhanced downstream signaling
may also result (de Haij et al. 2010). In the present study,
enavatuzumab exerted only modest growth inhibition on
ER ? MCF7 cells in vitro, and only when the antibody
was immobilized. However, in vivo, enavatuzumab treat-
ment resulted in regression of MCF7 tumors (Fig. 3a). The
apparent discrepancy between responses in vitro and
in vivo is likely a result of in vivo Fc–FcR interactions, as a
version of enavatuzumab containing a mutation preventing
Fc–FcR interactions did not inhibit the growth of MCF7
tumors (data not shown). Fc–FcR-dependent activity of
enavatuzumab in the MCF7 model may be a result of
ADCC, enhanced downstream signaling, or a combination
of both.
TweakR expression did not correlate directly in
response to enavatuzumab in vitro. However, TweakR is
upregulated by serum and other growth factors (Meighan-
Mantha et al. 1999), and the vast majority of human breast
cancer cell lines tested expressed significant levels of
TweakR under standard growth conditions in vitro which
does not necessarily reflect the tumor growth environment
in vivo. Indeed, TweakR expression was observed in a
smaller subset of primary breast cancer samples than in
cultured cells in vitro. Thus, it is not clear whether the level
of TweakR expression might correlate with sensitivity to
enavatuzumab in vivo although a minimal level of TweakR
expression is necessary for efficacy.
The observation that TweakR is expressed in multiple
subtypes of breast cancer and that enavatuzumab exhibits
potent in vitro and in vivo activity, both as monotherapy
and in combination with other agents, provides the ratio-
nale for further evaluation of enavatuzumab for the treat-
ment of breast cancer.
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